TNFRSF17 and neoplasm: Dual suppression promotes immune activation and complements immunotherapies such as anti-PD-1 or anti-BCMA (55).This strategy not only helps inhibit tumor angiogenesis but may also boost the effectiveness of immunotherapy by reducing the accumulation of suppressor cells (106).